Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel.

@article{Fader2009AbraxaneFT,
  title={Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel.},
  author={Amanda N Fader and Peter G Rose},
  journal={International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  year={2009},
  volume={19 7},
  pages={
          1281-3
        }
}
BACKGROUND Paclitaxel is used in the treatment of most gynecologic malignancies. It is solubilized in Cremophor EL, a polyoxyethylated castor oil agent responsible for the high rate of paclitaxel-associated hypersensitivity reactions. Abraxane, a newer, Cremophor-free form of albumin bound paclitaxel has demonstrated an activity and an improved toxicity profile in breast and lung cancers. CASE REPORTS Five patients with gynecologic cancers (2 ovarian, 2 endometrial, and 1 cervical malignancy… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-8 of 8 references

Hypersensitivity reactions to systemic chemotherapy

  • HB Koon, RE Drews
  • In: Rose BD (ed), Up-To-Date,
  • 2008
1 Excerpt

ABI-007 (Abraxane) a nanoparticle albumin-bound paclitaxel demonstrates superior efficacy vs. Taxol in MBC: a phase III trial

  • JA O’Shaughnessy, S Tjulandin, N. Davison
  • 26th Annual San Antonio Breast Cancer Symposium
  • 2003
1 Excerpt

Similar Papers

Loading similar papers…